丨2026年2月24日星期二丨 NO.1 和铂医药就新一代CTLA-4抗体达成授权协议及股权合作 2月23日,和铂医药公告称,公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协议。据此,公司同意向Solstice Oncology授予独家授权,以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。根据该等协议的条款,公司有资格获得价值超过1.05亿美元...
Source Link丨2026年2月24日星期二丨 NO.1 和铂医药就新一代CTLA-4抗体达成授权协议及股权合作 2月23日,和铂医药公告称,公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协议。据此,公司同意向Solstice Oncology授予独家授权,以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。根据该等协议的条款,公司有资格获得价值超过1.05亿美元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.